Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 May 7;9(5):543.
doi: 10.3390/healthcare9050543.

Ixekizumab May Improve Renal Function in Psoriasis

Giuseppe Fabrizio Amoruso  1 , Steven Paul Nisticò  2 , Luigi Iannone  2 , Emilio Russo  2 , Giuseppe Rago  3 , Cataldo Patruno  2 , Luigi Bennardo  2
Affiliations
Case Reports

Ixekizumab May Improve Renal Function in Psoriasis

Giuseppe Fabrizio Amoruso et al. Healthcare (Basel). .

Abstract

Background: Psoriasis is a chronic dermatological condition characterized by lesions on extensor surfaces, hands, feet, and genital areas. Chronic renal failure is often associated with metabolic syndrome and inflammatory conditions, such as psoriasis.

Case report: In this paper, we report a patient with stage-three chronic renal failure that improved his renal condition after treatment with ixekizumab, an anti-IL17A drug used in the treatment of various cutaneous and rheumatological conditions.

Conclusions: IL17A blockage may help to treat various autoimmune and inflammatory conditions, such as psoriasis, that may lead to renal impairment. Further investigation is necessary in order to prove the effectiveness of this drug in renal conditions.

Keywords: chronic renal failure; ixekizumab; psoriasis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(A) Patient at baseline genital area; (B) patient at baseline left arm; (C) patient after one year, genital area; (D) patient after one year, left arm.
See this image and copyright information in PMC

References

    1. Dattola A., Silvestri M., Bennardo L., Del Duca E., Longo C., Bianchi L., Nisticò S. Update of calcineurin inhibitors to treat inverse psoriasis: A systematic review. Dermatol. Ther. 2018;31:e12728. doi: 10.1111/dth.12728. - DOI - PubMed
    1. Passante M., Dastoli S., Nisticò S.P., Bennardo L., Patruno C. Effectiveness of brodalumab in acrodermatitis continua of Hallopeau: A case report. Dermatol. Ther. 2020;33:e13170. doi: 10.1111/dth.13170. - DOI - PubMed
    1. Iannone L.F., Bennardo L., Palleria C., Roberti R., De Sarro C., Naturale M.D., Dastoli S., Donato L., Manti A., Valenti G., et al. Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study. PLoS ONE. 2020;15:e0241575. doi: 10.1371/journal.pone.0241575. - DOI - PMC - PubMed
    1. Kamiya K., Kishimoto M., Sugai J., Komine M., Ohtsuki M. Risk factors for the development of psoriasis. Int. J. Mol. Sci. 2019;20:4347. doi: 10.3390/ijms20184347. - DOI - PMC - PubMed
    1. Wild J., Hobohm L., Münzel T., Wenzel P., Steinbrink K., Karbach S., Keller K. Psoriasis and its impact on in-hospital outcome in patients hospitalized with acute kidney injury. J. Clin. Med. 2020;9:3004. doi: 10.3390/jcm9093004. - DOI - PMC - PubMed

Publication types

LinkOut - more resources